NATURE OF OPERATIONS (Narrative) (Details) $ in Thousands, € in Millions |
1 Months Ended | 3 Months Ended | 6 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Apr. 17, 2025
USD ($)
|
Mar. 31, 2025
EUR (€)
|
Mar. 31, 2025
USD ($)
|
Jun. 30, 2026
USD ($)
|
Dec. 31, 2025
USD ($)
|
Jun. 30, 2025
USD ($)
|
Mar. 31, 2025
EUR (€)
|
Mar. 31, 2025
USD ($)
|
Jun. 30, 2026
EUR (€)
|
Jun. 30, 2026
USD ($)
|
Jun. 30, 2025
USD ($)
|
|
| Nature Of Operations [Line Items] | |||||||||||
| Accumulated deficit | $ 244,418 | $ 237,010 | $ 244,418 | ||||||||
| Research and development expenses | 3,719 | $ 4,646 | 6,505 | $ 13,489 | |||||||
| Omnichem [Member] | |||||||||||
| Nature Of Operations [Line Items] | |||||||||||
| Funds committed | € 2.7 | $ 2,900 | |||||||||
| Other long-term liabilities | $ 1,450 | 1,450 | |||||||||
| Research and development expenses | 2,600 | ||||||||||
| Installment One [Member] | Omnichem [Member] | |||||||||||
| Nature Of Operations [Line Items] | |||||||||||
| Funds committed | € 1.3 | $ 1,400 | |||||||||
| Installment Two [Member] | Omnichem [Member] | |||||||||||
| Nature Of Operations [Line Items] | |||||||||||
| Funds committed | € 1.4 | $ 1,500 | |||||||||
| Mayne Pharma Group Limited [Member] | Product Purchase Agreement [Member] | |||||||||||
| Nature Of Operations [Line Items] | |||||||||||
| Consideration for agreement | $ 16,000 | $ 6,000 | $ 10,000 | ||||||||
| Contract termination description | This agreement was executed following the mutual termination by Sol-Gel and Galderma of the exclusive five-year license agreement in the U.S. for both products | ||||||||||